Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1beta protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1beta protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1alpha on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats[1][2][3].
Molecular Weight:
237.34
Purity:
95.55
CAS Number:
[77102-28-4]
Formula:
C7H15N3O2S2
Target:
Bradykinin Receptor,Carboxypeptidase,Interleukin Related
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
